IXYS Introduces New 4.5kV Press-Pack IGBT with Record

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
43
IXYS Introduces New 4.5kV Press-Pack IGBT with Record Current Rating and Record Power Density

LEIDEN, Netherlands and CHIPPENHAM, United Kingdom, May 16, 2017 (GLOBE NEWSWIRE) -- IXYS Corporation (NASDAQ: IXYS ) an international power and IC semiconductor company, today announced that its wholly owned UK subsidiary, IXYS UK Westcode Ltd., launched a new 4.5kV press-pack IGBT. The new asymmetric blocking device with a continuous DC rating of 2.8kV has a record breaking DC current rating of 3000A and repetitive peak collector current of 6000A.

The new 4.5kV device incorporates proven IGBT technology and is constructed using the IXYS proprietary integration technology at a larger scale than the current state of the art. It has a record current rating of 2400A at the same 4.5kV blocking voltage. The unique IGBT die design enables the encapsulation and integration in a fully hermetic package known as a ‘hockey puck’. The package is 26mm thick with a 132mm electrode diameter, larger than the established 2400A device, but maintains the same 170mm overall diameter as the lower power design. This gives an effective 25% more current rating in the same package envelope, and achieves the record-setting power density.

The robust internal construction is ‘die attach free’, with the dies directly pressure contacted through metallic contacts and external copper electrodes. The direct bond free contact ensures highest reliability and unrivalled thermal cycling properties, far exceeding those of conventionally packaged plastic power modules. The package design is based on IXYS UK’s well-established and proven technology, with the same advantages of hermeticity, enhanced ruggedness, explosion proof, and double side cooling. These IGBTs are rugged to more than ten times the short circuit energy of conventional plastic packaged modules. These unique properties make the new device an ideal solution where high reliability, maximum power density, and stability are important even after a failure.

In particular, the short circuit failure mode makes these devices the obvious choice for applications requiring series operation. Such is the case in utilities, HVDC, and very large medium voltage drives. The unrivalled current rating can also reduce the number of parallel paths required in very high current applications in the multi-megawatt range. The devices are also well suited to harsh environments and where maintenance access is difficult such as offshore marine and wind. The hermetic structure and high rupture resistance are properties that are particularly relevant in harsh environments where explosive failures and plasma leaks are unacceptable, such as mining, gas and oil instillations.

To facilitate the application of this new higher rated press-pack IGBT, IXYS UK Westcode has also launched a new complementary diode in its range of very high di/dt HP Sonic FRDs. This new diode is constructed using a new die bonding technology to maximise reliability. Packaged in an 85mm electrode 26mm thick package, the diode is pressure compatible with the press-pack IGBT so it can be mounted in the same series string for compact three level inverter configurations.

“This new device is only possible due to IXYS UK’s long experience in manufacturing and deep understanding of the principles of very large press-pack IGBTs with multiple parallel die and the evolving improvements in design achieved with this knowledge. IXYS believe this new device, at 6000A, to be the highest genuine current rating press-pack IGBT available today on the open market, which breaks completely new ground in the power handling capacity of a single device,” commented Frank Wakeman, IXYS UK’s Marketing and Technical Support Manager.

The part number designation for this reverse conduction press-pack IGBT is T2960GB45E and the compatible HP sonic FRD is part number E3000TC45E.

Typical applications include: utilities and HVDC applications, flexible AC transition systems, HVDC transition, statcoms, VSC SVC etc., medium voltage AC drives for harsh environments and ultra-high power, such as mining, marine and off shore, gas and oil installations, renewable energy for wind turbines, hydro generation, wave-generation and solar, plus any application where high power density and reliability are key considerations.

For data sheets please go to the IXYS UK website at www.ixysuk.com or please contact us at (email: sales@ixysuk.com ) or telephone: +44 (0)1249 444524 for quotation.

About IXYS UK

Located in Chippenham, England, IXYS UK Westcode Ltd is the IXYS leading manufacturing site for very high power thyristors, SCRs and rectifiers ranging up to 7200 Volts and 15,000 Amps.  IXYS UK continues to supply high technology components for a wide range of applications such as wind and solar energy, welding, AC and DC motor drives for oil, marine and water treatment facilities, uninterruptible power supplies, motor soft starters, transportation, induction heating, mining equipment and many other industrial applications.

About IXYS Corporation

Since its founding, IXYS Corporation has been developing power semiconductors and mixed signal ICs to improve power conversion efficiency, generate solar and wind power and provide efficient motor control for industrial applications.  IXYS, and its subsidiary companies, offer a diversified product base that addresses worldwide needs for power control in the growing cleantech industries, renewable energy markets, telecommunications, medical devices, transportation applications, flexible displays and RF power.

Safe Harbor Statement

Any statements contained in this press release that are not statements of historical fact, including the performance, features and suitability of products for various applications, may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of IXYS to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in the Company's SEC reports, including its Form 10-Q for the fiscal quarter ended December 31, 2016. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements.

Contacts:  Frank Wakeman, IXYS UK Westcode Limited, Chippenham, SN15 1GE, United Kingdom. +44 (0)1249 444524 Ray Segall, IXYS Long Beach 562-296-6584 (US sales enquiries only)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 2

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 1

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 1

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 5

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 1

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 7

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 8

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 3

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 2

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 10

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

Acumen Pharmaceuticals to Showcase Innovations at Conference

Updated Category News Views 115

Acumen Pharmaceuticals to Present at Health Conference Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a pioneering clinical-stage biopharmaceutical company, is set to engage in a significant fireside chat at the 7th Annual Evercore ISI HealthCONx Conference. This event will happen shortly, providing a platform for Acumen to discuss their innovative approaches to tackling...

Continue Reading
Chanson International Holding Reports Fiscal Year 2025 Mid-Year Results

Updated Category News Views 192

Chanson International Holding Reports Mid-Year Financial Results Chanson International Holding (NASDAQ: CHSN) has recently unveiled its financial performance for the first half of the fiscal year 2025. As a key player in the bakery and beverage sectors, the company's unaudited results signify its resilience in a fluctuating market. Overview of Financial Performance...

Continue Reading
Investors Are Strategically Analyzing REGN Options Activity

Updated Category News Views 66

Examining Recent Changes in REGN Options There's been a noteworthy shift in sentiment among financial experts regarding Regeneron Pharmaceuticals. A recent analysis of the trading patterns in REGN options has revealed a blend of bullish and bearish movements in the market. This information serves as a foundation for understanding the current factors that are shaping...

Continue Reading
Analysts Raise Price Targets for CVS After Strong Earning Report

Updated Category News Views 99

CVS Health Exceeds Expectations with Recent Earnings CVS Health Corp (NYSE: CVS) delivered an impressive earnings report for its fourth quarter, showing robust sales numbers that surpassed analysts' expectations. The company announced fourth-quarter sales totaling an incredible $97.71 billion, outpacing the consensus estimate of $97.19 billion. Adjusted Earnings Report...

Continue Reading
Healthcare Triangle and Teyame AI Join Forces to Innovate Patient Engagement

Updated Category News Views 161

Healthcare Triangle Announces Strategic Partnership with Teyame AI Healthcare Triangle, Inc. (Nasdaq: HCTI) is excited to share its recent agreement with Teyame AI LLC, a visionary corporation aiming to revolutionize customer experience through artificial intelligence. This partnership is a transformative step that will not only enhance HCTI's SaaS capabilities but is...

Continue Reading